Mac Keon et al., 2019 - Google Patents
Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells as antigen source in DC-based vaccination in the B16-F1 murine melanoma modelMac Keon et al., 2019
View HTML- Document ID
- 2456107299227707769
- Author
- Mac Keon S
- Bentivegna S
- Levy E
- Marks M
- Mantegazza A
- Wainstok R
- Mordoh J
- Publication year
- Publication venue
- Vaccine
External Links
Snippet
A major obstacle to obtaining relevant results in cancer vaccination has been the lack of identification of immunogenic antigens. Dendritic cell (DC)-based cancer vaccines used preventively may afford protection against tumor inoculation, but the effect of antigen choice …
- 239000000427 antigen 0 title abstract description 45
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7712970B2 (en) | Identifying neoantigens using hotspots | |
| JP7763588B2 (en) | Method for identifying neoantigens for T cell therapy | |
| JP6925980B2 (en) | Vaccines for the treatment and prevention of cancer | |
| JP7480064B2 (en) | Methods for identifying neoantigens using pan-allelic models | |
| JP7668742B2 (en) | Identification of neoantigens using MHC class II models | |
| Brennick et al. | Neoepitopes as cancer immunotherapy targets: key challenges and opportunities | |
| Martin Lluesma et al. | Cancer vaccines in ovarian cancer: how can we improve? | |
| CN109803981B (en) | Novel peptides and scaffolds for immunotherapy of head and neck squamous cell carcinoma and other cancers | |
| WO2018102585A1 (en) | Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations | |
| Terbuch et al. | Next generation cancer vaccines—make it personal! | |
| Stegantseva et al. | Multi-antigen DNA vaccine delivered by polyethylenimine and Salmonella enterica in neuroblastoma mouse model | |
| Melacarne et al. | Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides | |
| Sedlacek et al. | Phenotypically distinct helper NK cells are required for gp96-mediated anti-tumor immunity | |
| Parney et al. | Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma | |
| Kono et al. | Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery | |
| TW202035441A (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
| Zeng et al. | An epitope encoded by uORF of RNF10 elicits a therapeutic anti-tumor immune response | |
| DeVette et al. | A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer | |
| Mac Keon et al. | Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells as antigen source in DC-based vaccination in the B16-F1 murine melanoma model | |
| DeLeo et al. | Development of multi-epitope vaccines targeting wild-typesequence p53 peptides | |
| US12102672B2 (en) | Immunogenic sequences from a phage tail length tape measure protein, bacteria expressing the same and their use in treating a cancer | |
| Zhao et al. | A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen | |
| Rao et al. | Mutant epitopes in cancer | |
| Aurisicchio et al. | Patented cancer vaccines: the promising leads | |
| Weng et al. | Identification of human idiotype-specific T cells in lymphoma and myeloma |